Table 3.
Major trials with CD22-targeting CAR T-cells.
| Reference | Costimulatory Domain | Study Population and Median Age | Design | N | Prior CD19 CAR | CR (%) MRD-CR (%) |
Survival | CRS (%) Grade ≥ 3 (%) |
ICANS (%) Grade ≥ 3 (%) |
|---|---|---|---|---|---|---|---|---|---|
| NCT02315612 [65,66] | 4-1 BB | Pediatric and young adults 17.5 y |
Phase 1 | 58 | 62% | 70% 43% |
Median OS: 13.4 m | 86% 76% |
33% 2% |
| ChiCTR-OIC-17013523 [67] | 4-1 BB | Pediatric and adults 10 y |
NA | 34 | 91% | 71% 53% |
NA | 91% 3% |
18% 0% |
| NCT04088890 [68] | NA | Pediatric and adults 23 y |
Phase 1b | 16 | 58% | 75% 56% |
NA | 72% 6% |
6% 6% |
| NCT02650414 [69] | 4-1 BB | Pediatric and young adults 16 y |
Phase 1 | 17 | 94% | 77% 59% |
Median OS: 16.5 m Median EFS: 5.8 m |
82% 0% |
35% 0% |